Pfizer cites a recent analysis of an open-label trial of 8,888 patients in announcing its Lipitor, the leading cholesterol drug, reduces the risk of heart problems and hospital costs. The risk reduction in patients with heart disease led to a 21% decrease in hospitalization costs during the five years of the study when compared with simvastatin.

Full Story:

Related Summaries